Compare BOOM & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOOM | MXCT |
|---|---|---|
| Founded | 1965 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.8M | 155.8M |
| IPO Year | 1995 | 2021 |
| Metric | BOOM | MXCT |
|---|---|---|
| Price | $7.79 | $1.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $8.00 | $4.11 |
| AVG Volume (30 Days) | 769.2K | ★ 1.5M |
| Earning Date | 10-27-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 89.02 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $609,840,000.00 | $33,026,000.00 |
| Revenue This Year | $2.69 | $4.77 |
| Revenue Next Year | $5.90 | $10.06 |
| P/E Ratio | $22.03 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.69 | $0.64 |
| 52 Week High | $9.79 | $1.81 |
| Indicator | BOOM | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 56.85 | 40.93 |
| Support Level | $6.70 | $1.02 |
| Resistance Level | $8.72 | $1.27 |
| Average True Range (ATR) | 0.73 | 0.17 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 55.74 | 16.89 |
DMC Global Inc operates a diversified family of technical product and process businesses serving the energy, industrial and infrastructure markets. Its business is organized into three segments: Arcadia, DynaEnergetics, and NobelClad. Arcadia Products supplies architectural building products, including exterior and interior framing systems, windows, urtain walls, storefronts etc to the commercial construction market. NobelClad is involved in the production of explosion-welded clad metal plates for use in the construction of corrosion-resistant industrial processing equipment and specialized transition joints. DynaEnergetics driver, designs manufactures and distributes products utilized by the oil and gas industry principally for the perforation of oil and gas wells.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.